サマリー

中東・アフリカの急性リンパ球性/リンパ芽球性白血病（ALL）診断薬市場は、2023年から2030年の予測期間に5.7％の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2020年のデータを含み、計算の基準年は2021年で、予測期間は2023年から2030年です
市場セグメンテーション
中東・アフリカの急性リンパ性／リンパ芽球性白血病（ALL）診断薬市場、製品タイプ別（機器および消耗品・アクセサリー）、検査タイプ別（画像検査、生検、血液検査、その他）、がんタイプ別（B細胞リンパ芽球性白血病／リンパ腫、T細胞リンパ芽球性白血病）、年齢層別（21歳未満、21〜29、30〜65、65以上）、性別（男性、女性）エンドユーザー（病院、提携研究所、独立診断研究所、画像診断センター、がん研究機関、その他）、流通チャネル（直接入札、小売販売）、国（南アフリカ、サウジアラビア、UAE、エジプト、イスラエル、その他中東・アフリカ）産業動向と2030年予測
中東・アフリカの急性リンパ性／リンパ芽球性白血病（ALL）診断薬市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 白血病がん診断の認知度向上
- 予防検診への嗜好の高まり
市場のプレーヤー：

中東・アフリカの急性リンパ性／リンパ芽球性白血病（ALL）診断薬市場で活動している主なプレイヤーは以下の通りです：

- F. ホフマン・ラ・ロシュ社
- サーモフィッシャーサイエンティフィック（株
- QIAGEN
- アボット
- メルクKGgA
- ホロジック社
- アジレント・テクノロジー株式会社
- DiaSorin S.p.A.
- イルミナ・インコーポレイテッド
- クエスト・ダイアグノスティックス・インコーポレイテッド
- シーメンス・メディカル・ソリューションズUSA, Inc.
- バイオ・ラッド・ラボラトリーズ・インク
- フィリップスN.V.
- BD
- ミンファウンドメディカルシステムズ株式会社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 26
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 PRODUCT TYPE LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET TESTING TYPE COVERAGE GRID 39
2.11 VENDOR SHARE ANALYSIS 40
2.12 SECONDARY SOURCES 41
2.13 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 45
4.1 PESTEL ANALYSIS 46
4.2 PORTER’S FIVE FORCES 47
4.3 INDUSTRY INSIGHTS 48
5 EPIDEMIOLOGY 50
6 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 51
7 MARKET OVERVIEW 54
7.1 DRIVERS 56
7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 56
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 56
7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 57
7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 57
7.2 RESTRAINTS 59
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 59
7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 60
7.3 OPPORTUNITIES 60
7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 60
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 61
7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 61
7.4 CHALLENGES 62
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 62
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 63
8 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 64
8.1 OVERVIEW 65
8.2 INSTRUMENTS 68
8.2.1 BIOPSY INSTRUMENTS 69
8.2.1.1 BONE MARROW BIOPSY 69
8.2.1.2 NEEDLE BIOPSY 69
8.2.1.3 SURGEON BIOPSY 70
8.2.1.4 OTHERS 70
8.2.2 PATHOLOGY-BASED INSTRUMENTS 70
8.2.2.1 PCR INSTRUMENTS 70
8.2.2.2 SLIDE STAINING SYSTEMS 70
8.2.2.3 TISSUE PROCESSING SYSTEMS 70
8.2.2.4 CELL PROCESSORS 71
8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 71
8.2.3 IMAGING INSTRUMENTS 71
8.2.3.1 ULTRASOUND SYSTEMS 71
8.2.3.2 CT SYSTEMS 71
8.2.3.3 MRI SYSTEMS 71
8.2.3.4 OTHERS 72
8.2.4 OTHERS 72
8.3 CONSUMABLES & ACCESSORIES 72
8.3.1 KITS 73
8.3.1.1 PCR KITS 73
8.3.1.2 DNA POLYMERASE KITS 73
8.3.1.3 NUCLEIC ACID ISOLATION KITS 73
8.3.1.4 OTHERS 74
8.3.2 REAGENTS 74
8.3.2.1 ASSAYS 74
8.3.2.2 BUFFERS 74
8.3.2.3 PRIMERS 74
8.3.2.4 OTHERS 74
8.3.3 PROBES 75
8.3.4 OTHER CONSUMABLES 75
9 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 76
9.1 OVERVIEW 77
9.2 BIOPSY 80
9.2.1 BONE MARROW BIOPSY 81
9.2.2 NEEDLE BIOPSY 81
9.2.3 SURGEON BIOPSY 81
9.2.4 OTHERS 81
9.3 BLOOD TEST 82
9.3.1 BLOOD CHEMISTRY TESTS 83
9.3.2 COMPLETE BLOOD COUNT (CBC) 83
9.3.3 OTHERS 83
9.4 IMAGING TEST 83
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 84
9.4.2 MRI 84
9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 85
9.4.4 OTHERS 85
9.5 OTHERS 85
10 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 86
10.1 OVERVIEW 87
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 90
10.2.1 EARLY PRE-B ALL 91
10.2.2 COMMON ALL 91
10.2.3 PRE-B ALL 91
10.2.4 MATURE B-CELL ALL 91
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 91
10.3.1 PRE-T ALL 92
10.3.2 MATURE T-CELL ALL 92
11 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 93
11.1 OVERVIEW 94
11.2 BELOW 21 97
11.3 21-29 98
11.4 30-65 99
11.5 65 AND ABOVE 100
12 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 101
12.1 OVERVIEW 102
12.2 MALE 105
12.3 FEMALE 106
13 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 107
13.1 OVERVIEW 108
13.2 HOSPITALS 111
13.3 ASSOCIATED LABS 111
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 112
13.5 DIAGNOSTIC IMAGING CENTERS 113
13.6 CANCER RESEARCH INSTITUTES 113
13.7 OTHERS 114
14 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 115
14.1 OVERVIEW 116
14.2 DIRECT TENDER 119
14.3 RETAIL SALES 120
15 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 121
15.1 MIDDLE EAST AND AFRICA 122
15.1.1 SOUTH AFRICA 133
15.1.2 EGYPT 138
15.1.3 SAUDI ARABIA 143
15.1.4 ISRAEL 148
15.1.5 UAE 153
15.1.6 REST OF MIDDLE EAST AND AFRICA 158
16 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 159
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 159
17 SWOT ANALYSIS 160
18 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 161
18.1 F. HOFFMANN-LA ROCHE LTD. 161
18.1.1 COMPANY SNAPSHOT 161
18.1.2 REVENUE ANALYSIS 161
18.1.3 COMPANY SHARE ANALYSIS 162
18.1.4 PRODUCT PORTFOLIO 162
18.1.5 RECENT DEVELOPMENT 162
18.2 THERMO FISHER SCIENTIFIC INC. 163
18.2.1 COMPANY SNAPSHOT 163
18.2.2 REVENUE ANALYSIS 163
18.2.3 COMPANY SHARE ANALYSIS 164
18.2.4 PRODUCT PORTFOLIO 164
18.2.5 RECENT DEVELOPMENT 164
18.3 QIAGEN 165
18.3.1 COMPANY SNAPSHOT 165
18.3.2 REVENUE ANALYSIS 165
18.3.3 COMPANY SHARE ANALYSIS 166
18.3.4 PRODUCT PORTFOLIO 166
18.3.5 RECENT DEVELOPMENT 166
18.4 ABBOTT 167
18.4.1 COMPANY SNAPSHOT 167
18.4.2 REVENUE ANALYSIS 167
18.4.3 COMPANY SHARE ANALYSIS 168
18.4.4 PRODUCT PORTFOLIO 168
18.4.5 RECENT DEVELOPMENT 168
18.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 169
18.5.1 COMPANY SNAPSHOT 169
18.5.2 REVENUE ANALYSIS 169
18.5.3 COMPANY SHARE ANALYSIS 170
18.5.4 PRODUCT PORTFOLIO 170
18.5.5 RECENT DEVELOPMENT 170
18.6 MERCK KGAA 171
18.6.1 COMPANY SNAPSHOT 171
18.6.2 REVENUE ANALYSIS 171
18.6.3 PRODUCT PORTFOLIO 172
18.6.4 RECENT DEVELOPMENT 172
18.7 HOLOGIC INC. 173
18.7.1 COMPANY SNAPSHOT 173
18.7.2 REVENUE ANALYSIS 173
18.7.3 PRODUCT PORTFOLIO 174
18.7.4 RECENT DEVELOPMENT 174
18.8 AGILENT TECHNOLOGIES, INC. 175
18.8.1 COMPANY SNAPSHOT 175
18.8.2 REVENUE ANALYSIS 175
18.8.3 PRODUCT PORTFOLIO 176
18.8.4 RECENT DEVELOPMENT 176
18.9 BD 177
18.9.1 COMPANY SNAPSHOT 177
18.9.2 REVENUE ANALYSIS 177
18.9.3 PRODUCT PORTFOLIO 178
18.9.4 RECENT DEVELOPMENT 178
18.10 BIOMÉRIEUX SA 179
18.10.1 COMPANY SNAPSHOT 179
18.10.2 REVENUE ANALYSIS 179
18.10.3 PRODUCT PORTFOLIO 180
18.10.4 RECENT DEVELOPMENTS 180
18.11 BIO-RAD LABORATORIES, INC. 181
18.11.1 COMPANY SNAPSHOT 181
18.11.2 REVENUE ANALYSIS 181
18.11.3 PRODUCT PORTFOLIO 182
18.11.4 RECENT DEVELOPMENT 182
18.12 DIASORIN S.P.A. 183
18.12.1 COMPANY SNAPSHOT 183
18.12.2 REVENUE ANALYSIS 183
18.12.3 PRODUCT PORTFOLIO 184
18.12.4 RECENT DEVELOPMENTS 184
18.13 EXACT SCIENCE CORPORATION 185
18.13.1 COMPANY SNAPSHOT 185
18.13.2 REVENUE ANALYSIS 185
18.13.3 PRODUCT PORTFOLIO 186
18.13.4 RECENT DEVELOPMENT 186
18.14 ILLUMINA, INC. 187
18.14.1 COMPANY SNAPSHOT 187
18.14.2 REVENUE ANALYSIS 187
18.14.3 PRODUCT PORTFOLIO 188
18.14.4 RECENT DEVELOPMENT 188
18.15 KONINKLIJKE PHILIPS N.V. 189
18.15.1 COMPANY SNAPSHOT 189
18.15.2 REVENUE ANALYSIS 189
18.15.3 PRODUCT PORTFOLIO 190
18.15.4 RECENT DEVELOPMENT 190
18.16 MEDONICA CO. LTD 191
18.16.1 COMPANY SNAPSHOT 191
18.16.2 PRODUCT PORTFOLIO 191
18.16.3 RECENT DEVELOPMENT 191
18.17 MICHAEL DIAGNOSTICS LTD 192
18.17.1 COMPANY SNAPSHOT 192
18.17.2 PRODUCT PORTFOLIO 192
18.17.3 RECENT DEVELOPMENT 192
18.18 MINFOUND MEDICAL SYSTEMS CO., LTD 193
18.18.1 COMPANY SNAPSHOT 193
18.18.2 PRODUCT PORTFOLIO 193
18.18.3 RECENT DEVELOPMENT 193
18.19 MYRIAD GENETICS, INC. 194
18.19.1 COMPANY SNAPSHOT 194
18.19.2 REVENUE ANALYSIS 194
18.19.3 PRODUCT PORTFOLIO 195
18.19.4 RECENT DEVELOPMENT 195
18.20 PLEXBIO 196
18.20.1 COMPANY SNAPSHOT 196
18.20.2 PRODUCT PORTFOLIO 196
18.20.3 RECENT DEVELOPMENTS 196
18.21 QUEST DIAGNOSTICS INCORPORATED 197
18.21.1 COMPANY SNAPSHOT 197
18.21.2 REVENUE ANALYSIS 197
18.21.3 PRODUCT PORTFOLIO 198
18.21.4 RECENT DEVELOPMENTS 198
18.22 STERNMED GMBH 199
18.22.1 COMPANY SNAPSHOT 199
18.22.2 PRODUCT PORTFOLIO 199
18.22.3 RECENT DEVELOPMENTS 199
18.23 TIME MEDICAL HOLDING 200
18.23.1 COMPANY SNAPSHOT 200
18.23.2 PRODUCT PORTFOLIO 200
18.23.3 RECENT DEVELOPMENT 200
19 QUESTIONNAIRE 201

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 60
TABLE 2 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 67
TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 4 MIDDLE EAST & AFRICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 69
TABLE 5 MIDDLE EAST & AFRICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 69
TABLE 6 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 70
TABLE 7 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 71
TABLE 8 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 9 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 10 MIDDLE EAST & AFRICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 11 MIDDLE EAST & AFRICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 74
TABLE 12 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 79
TABLE 13 MIDDLE EAST & AFRICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 14 MIDDLE EAST & AFRICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 81
TABLE 15 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 16 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 83
TABLE 17 MIDDLE EAST & AFRICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 18 MIDDLE EAST & AFRICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 84
TABLE 19 MIDDLE EAST & AFRICA OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 20 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 89
TABLE 21 MIDDLE EAST & AFRICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 22 MIDDLE EAST & AFRICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 91
TABLE 23 MIDDLE EAST & AFRICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 24 MIDDLE EAST & AFRICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 92
TABLE 25 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 96
TABLE 26 MIDDLE EAST & AFRICA BELOW 21 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 27 MIDDLE EAST & AFRICA 21-29 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 28 MIDDLE EAST & AFRICA 30-65 IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 29 MIDDLE EAST & AFRICA 65 AND ABOVE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 30 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 104
TABLE 31 MIDDLE EAST & AFRICA MALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 32 MIDDLE EAST & AFRICA FEMALE IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 33 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 110
TABLE 34 MIDDLE EAST & AFRICA HOSPITALS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 35 MIDDLE EAST & AFRICA ASSOCIATED LABS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 36 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 37 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 38 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 39 MIDDLE EAST & AFRICA OTHERS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 40 MIDDLE EAST & AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 118
TABLE 41 MIDDLE EAST & AFRICA DIRECT TENDER IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
TABLE 42 MIDDLE EAST & AFRICA RETAIL SALES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 43 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 127
TABLE 44 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 45 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 46 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 47 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 48 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 49 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 50 MIDDLE EAST AND AFRICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 51 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 52 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 53 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 54 MIDDLE EAST AND AFRICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 55 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 56 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 130
TABLE 57 MIDDLE EAST AND AFRICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 131
TABLE 58 MIDDLE EAST AND AFRICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 131
TABLE 59 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 131
TABLE 60 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 131
TABLE 61 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
TABLE 62 MIDDLE EAST AND AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
TABLE 63 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 64 SOUTH AFRICA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 65 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 66 SOUTH AFRICA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 67 SOUTH AFRICA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 68 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 69 SOUTH AFRICA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 70 SOUTH AFRICA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
TABLE 71 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 72 SOUTH AFRICA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 73 SOUTH AFRICA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 74 SOUTH AFRICA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 136
TABLE 75 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 136
TABLE 76 SOUTH AFRICA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 136
TABLE 77 SOUTH AFRICA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 136
TABLE 78 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 137
TABLE 79 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 137
TABLE 80 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 137
TABLE 81 SOUTH AFRICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 137
TABLE 82 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 83 EGYPT INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 84 EGYPT PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 85 EGYPT IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 86 EGYPT BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 87 EGYPT CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 88 EGYPT KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 89 EGYPT REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 90 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 91 EGYPT IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 92 EGYPT BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 93 EGYPT BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 94 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 141
TABLE 95 EGYPT B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 141
TABLE 96 EGYPT T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 141
TABLE 97 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 142
TABLE 98 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 142
TABLE 99 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 142
TABLE 100 EGYPT ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 142
TABLE 101 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 143
TABLE 102 SAUDI ARABIA INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 143
TABLE 103 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 143
TABLE 104 SAUDI ARABIA IMAGING INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 105 SAUDI ARABIA BIOPSY INSTRUMENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 106 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 107 SAUDI ARABIA KITS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
TABLE 108 SAUDI ARABIA REAGENTS IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 109 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
TABLE 110 SAUDI ARABIA IMAGING TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
TABLE 111 SAUDI ARABIA BIOPSY IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
TABLE 112 SAUDI ARABIA BLOOD TEST IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 113 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 146
TABLE 114 SAUDI ARABIA B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 146
TABLE 115 SAUDI ARABIA T-CELL LYMPHOBLASTIC LEUKEMIA IN ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 146
TABLE 116 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 147
TABLE 117 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 147
TABLE 118 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 119 SAUDI ARABIA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 147